IN184589B - - Google Patents

Info

Publication number
IN184589B
IN184589B IN1756CA1997A IN184589B IN 184589 B IN184589 B IN 184589B IN 1756CA1997 A IN1756CA1997 A IN 1756CA1997A IN 184589 B IN184589 B IN 184589B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Victoria Marie Knepp
Steven Joseph Prestrelski
Jessica Gruber Smith
Manley Tin Fah Huang
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to IN44CA2000 priority Critical patent/IN188568B/en
Publication of IN184589B publication Critical patent/IN184589B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1756CA1997 1996-10-16 1997-09-23 IN184589B (cg-RX-API-DMAC7.html)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN44CA2000 IN188568B (cg-RX-API-DMAC7.html) 1996-10-16 2000-01-28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2816796P 1996-10-16 1996-10-16
US5292097P 1997-07-15 1997-07-15

Publications (1)

Publication Number Publication Date
IN184589B true IN184589B (cg-RX-API-DMAC7.html) 2000-09-09

Family

ID=26703379

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1756CA1997 IN184589B (cg-RX-API-DMAC7.html) 1996-10-16 1997-09-23

Country Status (10)

Country Link
US (3) US6264990B1 (cg-RX-API-DMAC7.html)
EP (1) EP0939655B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002513390A (cg-RX-API-DMAC7.html)
AR (1) AR008673A1 (cg-RX-API-DMAC7.html)
AT (1) ATE218886T1 (cg-RX-API-DMAC7.html)
AU (1) AU4821197A (cg-RX-API-DMAC7.html)
CA (1) CA2264776C (cg-RX-API-DMAC7.html)
DE (1) DE69713378T2 (cg-RX-API-DMAC7.html)
IN (1) IN184589B (cg-RX-API-DMAC7.html)
WO (1) WO1998016250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN184589B (cg-RX-API-DMAC7.html) * 1996-10-16 2000-09-09 Alza Corp
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
DE19940748A1 (de) * 1999-08-27 2001-03-01 Hugo Seinfeld Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
EP1263461A4 (en) * 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
JP2005505429A (ja) * 2001-06-28 2005-02-24 マイクロチップス・インコーポレーテッド マイクロチップリザーバデバイスを密閉シーリングするための方法
AU2002353013A1 (en) * 2001-12-03 2003-06-17 Massachusetts Institute Of Technology Microscale lyophilization and drying methods for the stabilization of molecules
ES2411656T3 (es) * 2002-03-13 2013-07-08 Thomas SKÖLD Sistemas de administración a base de agua
KR100725973B1 (ko) * 2002-08-16 2007-06-11 마이크로칩스 인코포레이티드 전열적 제거를 이용한 제어 방출 장치 및 방법
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
JP4791730B2 (ja) * 2002-09-27 2011-10-12 パウダージェクト リサーチ リミテッド 核酸コーティング粒子
EP1551499A1 (en) 2002-10-04 2005-07-13 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP3597262B1 (en) 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
AU2004229465B2 (en) * 2003-04-09 2010-04-29 The United States Of America Department Of Veterans Affairs Compositions and methods related to production of erythropoietin
CA2523432C (en) * 2003-04-25 2014-10-28 Microchips, Inc. Solid drug formulation and device for storage and controlled delivery thereof
US7892205B2 (en) * 2003-06-06 2011-02-22 Boston Scientific Scimed, Inc. Device and method for delivering micronized therapeutic agents in the body
US8095197B2 (en) * 2003-11-03 2012-01-10 Microchips, Inc. Medical device for sensing glucose
EP1765455A2 (en) * 2004-06-01 2007-03-28 Microchips, Inc. Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
EP1791643B1 (en) * 2004-09-01 2009-03-11 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
EP2995331B1 (en) 2004-09-10 2018-09-05 Becton, Dickinson and Company Reconstituting infusion device and method of reconstituting medicament
AU2006208131A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2643140T3 (es) * 2005-12-22 2017-11-21 Oakwood Laboratories L.L.C. Sistema de suministro de liberación lenta sublimable y procedimiento de realización del mismo
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
CA2681565C (en) * 2007-03-30 2016-10-25 John M. Docherty Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas HIGHLY CONCENTRATED LOW VISCOSITY SUSPENSIONS
EP3936122A1 (en) * 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CN103096934A (zh) * 2010-03-09 2013-05-08 詹森生物科技公司 非水性高浓度低粘度混悬剂
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101978527B1 (ko) 2011-03-10 2019-09-03 엑스에리스 파머수티클스, 인크. 펩티드 약물의 비경구 주입을 위한 안정한 제형
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
PL2714010T3 (pl) 2011-05-25 2017-08-31 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
MX361681B (es) 2012-01-23 2018-12-13 Novaliq Gmbh Composiciones de proteína estabilizadas basadas en alcanos semifluorados.
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
WO2014041071A1 (en) 2012-09-12 2014-03-20 Novaliq Gmbh Semifluorinated alkane compositions
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
SG10201707600XA (en) * 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
JP7097667B2 (ja) 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
US10772942B2 (en) * 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3169660A1 (en) 2014-07-16 2017-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102497368B1 (ko) 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3334417A4 (en) 2015-08-12 2019-07-17 Massachusetts Institute of Technology CELL SURFACE COUPLING OF NANOPARTICLES
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
EP3399962B1 (en) 2016-12-23 2020-06-10 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
BR112020017838A2 (pt) 2018-03-02 2020-12-22 Novaliq Gmbh Composições farmacêuticas que compreendem nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2019217637A1 (en) * 2018-05-09 2019-11-14 Biomatrica, Inc. Stabilization of proteins in biological samples
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
KR20210125032A (ko) 2019-02-05 2021-10-15 린디 바이오사이언시스, 아이엔씨. 세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
EP4069324B1 (en) 2019-12-06 2025-05-21 Guangzhou Bioseal Biotech Co., Ltd. Flowable fibrinogen thrombin paste
GB2615462A (en) * 2020-11-20 2023-08-09 Team Medical Llc RNA stabilization
US20230101362A1 (en) * 2021-09-16 2023-03-30 Team Medical Llc Rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2342073A1 (fr) 1976-02-27 1977-09-23 Merieux Inst Nouveau vaccin antivariolique sous forme de pate et son dispositif d'application
EP0177342A3 (en) 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
IT8922398A0 (it) 1989-11-16 1989-11-16 Phidea Spa Composizioni farmaceutiche ad elevato assorbimento e stabilita', comprendente una calcitonina come sostanza attiva.
US5518731A (en) * 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
AU5018693A (en) 1992-09-21 1994-04-12 Upjohn Company, The Sustained-release protein formulations
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
WO1996027393A1 (en) 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IN184589B (cg-RX-API-DMAC7.html) * 1996-10-16 2000-09-09 Alza Corp

Also Published As

Publication number Publication date
US6264990B1 (en) 2001-07-24
US20040151779A1 (en) 2004-08-05
EP0939655B1 (en) 2002-06-12
CA2264776C (en) 2008-11-25
AU4821197A (en) 1998-05-11
AR008673A1 (es) 2000-02-09
US6730328B2 (en) 2004-05-04
CA2264776A1 (en) 1998-04-23
DE69713378D1 (de) 2002-07-18
US20010038859A1 (en) 2001-11-08
DE69713378T2 (de) 2003-01-30
WO1998016250A1 (en) 1998-04-23
JP2002513390A (ja) 2002-05-08
EP0939655A1 (en) 1999-09-08
ATE218886T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
AR026659A2 (cg-RX-API-DMAC7.html)
BRPI9713914B8 (cg-RX-API-DMAC7.html)
IN184589B (cg-RX-API-DMAC7.html)
IN192215B (cg-RX-API-DMAC7.html)
IN192434B (cg-RX-API-DMAC7.html)
ITCA960004A0 (cg-RX-API-DMAC7.html)
BR9603859A (cg-RX-API-DMAC7.html)
ITMI960581A0 (cg-RX-API-DMAC7.html)
ITMI960373A0 (cg-RX-API-DMAC7.html)
BR7600721U (cg-RX-API-DMAC7.html)
BR7601346U (cg-RX-API-DMAC7.html)
CN3044169S (cg-RX-API-DMAC7.html)
CN3043413S (cg-RX-API-DMAC7.html)
CN3041374S (cg-RX-API-DMAC7.html)
CN3044347S (cg-RX-API-DMAC7.html)
CN3044175S (cg-RX-API-DMAC7.html)
CN3044174S (cg-RX-API-DMAC7.html)
CN3044173S (cg-RX-API-DMAC7.html)
CN3044348S (cg-RX-API-DMAC7.html)
CN3044172S (cg-RX-API-DMAC7.html)
CN3044170S (cg-RX-API-DMAC7.html)
CN3044349S (cg-RX-API-DMAC7.html)
CN3044168S (cg-RX-API-DMAC7.html)
CN3043418S (cg-RX-API-DMAC7.html)
CN3043417S (cg-RX-API-DMAC7.html)